Related Experiment Videos
Restoration of the transcription activation function to mutant p53 in human cancer cells
P Abarzúa1, J E LoSardo, M L Gubler
1Roche Research Center, Hoffmann-LaRoche Inc, Nutley, New Jersey 07110, USA.
Abstract:
The p53 tumor suppressor gene product is a sequence-specific transcription activator frequently mutated in a variety of human malignancies. Typically, tumor-derived p53 missense mutants are defective in DNA binding and this is likely to result in a failure to active p53-regulated genes. Hence, restoring function to mutant p53 represents an attractive target to develop a novel cancer chemotherapeutic agent. We now show that a small chemically modified peptide derived from p53 restores sequence-specific DNA binding to a subset of p53 mutants. Moreover, when microinjected into human colon carcinoma cells this peptide restores the transcription activation function to endogenous mutant p53 protein. This is the first example showing that a small peptide molecule can reverse the effect of several inactivating missense mutations and restore protein function.
Insights
A novel peptide derived from p53 can restore DNA binding and gene activation functions to mutant p53 protein, offering a potential new strategy for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The p53 protein is a crucial tumor suppressor and transcription activator.
- Mutations in p53 are common in human cancers, often leading to loss of DNA binding and gene regulation.
- Restoring p53 function is a promising therapeutic target for cancer treatment.
Purpose of the Study:
- To investigate if a small peptide can restore function to mutant p53.
- To evaluate the potential of peptide-based therapy for p53-mutated cancers.
Main Methods:
- A chemically modified peptide derived from p53 was synthesized.
- The peptide's ability to restore DNA binding to p53 mutants was assessed.
- The peptide's effect on transcription activation in human colon carcinoma cells was evaluated after microinjection.
Main Results:
- The peptide successfully restored sequence-specific DNA binding to a subset of p53 mutants.
- Microinjection of the peptide reactivated the transcription activation function of endogenous mutant p53 in cancer cells.
Conclusions:
- This study demonstrates that a small peptide can reverse the functional loss caused by several inactivating p53 missense mutations.
- This peptide-based approach represents a novel strategy for developing cancer therapeutics targeting p53 mutations.